corporate-venture

AbbVie's corporate venture arm, which invests in early-stage biotech companies in AbbVie's therapeutic areas including cancer. Its web pages blocked automated access at the time of research.

Alexandria Venture Investments is the venture arm of Alexandria Real Estate Equities, the life science property company, and takes small, non-lead stakes across a large number of biotech start-ups, often tenants of its campuses, in oncology and other areas. Its web pages blocked automated access, so its own strategy and named cancer companies are unconfirmed.

Amgen Ventures is the venture arm of the biotech company Amgen. It takes minority stakes in early companies whose science could matter to Amgen, including cancer drug and platform start-ups.

Alphabet's venture arm, established in 2009. It has backed some of the best-known cancer diagnostics companies, including Foundation Medicine, Grail, Freenome and Flatiron Health, as well as cancer drug developers such as Forty Seven and Gritstone.

An independently managed venture firm with a strategic tie to the sequencing company Illumina. It backs genomics and precision health start-ups, including cancer companies such as Delfi Diagnostics, Actym Therapeutics and Oncko.

Johnson & Johnson's venture capital arm, one of the oldest corporate venture groups in healthcare. It invests alongside J&J's innovation centres and JLABS incubators, including in cancer companies.

Bayer's impact investing unit, which funds companies tackling ten 'leaps' in health and agriculture, including curing cancer. Its website blocked automated access at the time of research.

Eli Lilly's investment arm, part of its Lilly Catalyze360 programme for early biotech companies. It co-invests with venture syndicates across all disease areas, including cancer.

McKesson Ventures is the venture arm of the drug distributor McKesson, which also owns the largest US community oncology network, so it backs companies that change how cancer care is delivered and paid for.

Merck & Co's corporate venture fund for digital health and healthcare services companies, known as MSD GHI outside North America. Its website is a JavaScript application whose content could not be read.

The Novartis Venture Fund is Novartis's corporate venture arm, run from Basel and Cambridge, Massachusetts, making seed and Series A investments of 5 to 10 million dollars in biotech companies, including the cancer drug developers Artios Pharma, CatalYm and Epsilogen. It manages over 750 million dollars across more than 40 companies.

Pfizer's corporate venture arm, which invests in early biotech companies in the areas Pfizer cares about, including cancer. Its oncology portfolio includes Artios Pharma, Crossbow Therapeutics and Strata Oncology.

Roche's corporate venture fund, based in Basel, which takes minority stakes in early biotech and diagnostics companies. Its web pages could not be located at the time of research.

Sanofi's strategic venture fund, which invests in early biotech and digital health companies before they are ready to partner with or be bought by Sanofi. Cancer-related holdings include the radiopharmaceutical company AdvanCell and the immune checkpoint company Abcuro.

Takeda Ventures, founded in 2001, is Takeda's corporate venture group, investing in preclinical, platform-based drug companies whose programmes complement Takeda's pipeline in oncology, rare genetics and haematology, neuroscience and gastrointestinal disease. Its page lists no portfolio companies, so no cancer examples are recorded here.